Publication Database

Efficacy of two omeprazole formulations for the therapy of equine gastric ulcer disease (2021)

Art

Poster

Autoren

Barton, Ann Kristin (WE 17)

Merle, Roswitha (WE 16)

Gehlen, Heidrun (WE 17)

Kongress

ECEIM Jahreskongress

online, 24. – 25.10.2021

Quelle

Sprache

Englisch

Verweise

URL (Volltext): https://www.eceim.info/system/files/poster-presentations/2021/poster-presentation-796.pdf

Kontakt

Pferdeklinik

Oertzenweg 19 b
14163 Berlin
+49 30 838 62299 / 62300
pferdeklinik@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Introduction:
Equine Gastric Ulcer Disease (EGUS) is a common problem in equine athletes. The ECEIM consensus statement and the manufacturers recommend omeprazole at a dosage of 2-4mg/kg PO SID (buffered formulations) and 1-2mg/kg PO SID (enteric coated granules) for the treatment of ESGD (Equine Squamous Gastric Disease) and the same in combination with sucralfate (12mg/kg PO BID) for EGGD (Equine Glandular Gastric Disease). In this study, the two formulations were compared in an equine hospital setting.

Methods:
A modified clinical scoring was used to include 87 horses (January 2019 - December 2020) presented for recurrent colic, weight loss, exercise insufficiency or typical behavior (bruxism, groaning), in which gastroscopy was performed. Horses were classified as 0-4 for ESGD (Consensus statement) and 0-3 for EGGD (modified from non-remarkable/mild/moderate/severe findings according to the Consensus statement). Omeprazole therapy (buffered formulation 4mg/kg PO SID, Gastrogard™, Boehringer Ingelheim or enteric coated granules 2mg/kg PO SID, Equizol™, CP Pharma), in case of EGGD combined with sucralfate (12 mg/kg PO BID, Sucrabest™, Combustin) was recommended in 63 horses; gastroscopy was repeated about 4 weeks later.

Results:
Both formulations were highly effective in improving ESGD ≥2 subgrades or achieving grade 0 in 93% and 100% of horses treated with buffered (Gastrogard™) and encapsulated formulations (Equizol™), respectively. EGGD was improved by ≥1 subgrade or achieving grade 0 in 64.3% and 71.4% of horses treated with buffered and enteric coated formulations combined with sucralfate, respectively. No significant differences between the two formulations
were found for neither ESGD nor EGGD (P > 0.999).

Discussion and Conclusions:
Both omeprazole formulations can be recommended for the treatment of EGUS, in particular ESGD. Differences in long-term effect and recurrence rates should be studied in future studies.